Influence of liver cirrhosis on sertraline pharmacokinetics

Authors: DÉMOLIS, JEAN-LOUIS¹; ANGEBAUD, PASCAL¹; GRANGÉ, JEAN-DIDIER²; COATES, PETER³; FUNCK-BRENTANO, CHRISTIAN¹; JAILLON, PATRICE¹

Source: British Journal of Clinical Pharmacology, Volume 42, Number 3, September 1996 , pp. 394-397(4)

Publisher: Wiley-Blackwell

Buy & download fulltext article:

Price: $48.00 plus tax (Refund Policy)

Abstract:

Sertraline is a serotonin reuptake inhibitor. The enhancement of serotoninergic transmission is associated with antidepressant activity. In order to determine the pharmacokinetics of sertraline in patients with chronic stable hepatic insufficiency, 10 patients were matched (age, weight, sex) with 10 healthy subjects in an open study. Each participant received a single capsule containing the equivalent of 100 mg sertraline base. Blood samples were taken during 264 h after administration for measurement of plasma concentrations of sertraline. The results confirm that the oral clearance of sertraline is reduced with a 1.7-fold increase in C_max and a significant prolongation in elimination half-life in hepatically impaired patients

Keywords: sertraline; pharmacokinetics; liver cirrhosis

Document Type: Research article

DOI: http://dx.doi.org/10.1046/j.1365-2125.1996.42817.x

Affiliations: 1: Clinical Pharmacology Unit, Saint-Antoine University Hospital, Paris, 2: Division of Gastroenterology, Tenon University Hospital, Paris, France, 3: Pfizer Central Research, Sandwich, Kent, UK

Publication date: 1996-09-01